RadioMedix   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Houston TX United States (2006)

Organization Overview

First Clinical Trial
2006
NCT00442533
First Marketed Drug
2020
cu-64 dotatate (Detectnet)
First NDA Approval
2020
cu-64 dotatate (Detectnet)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

RADIOMEDIX | Radiomedix, Inc.

Active Ingredients

Marketed Drugs (1)

cu-64 dotatate (Detectnet) (2020 NDA)

Drugs in Phase 3 Trials (2)

cu-64 dotatate (Detectnet) (1 trial)

in111-octreoscan (1 trial)

Drugs in Phase 2 Trials (3)

Ga 68 PSMA-11 (Illuccix) (1 trial)

gallium-68-dotatate (netspot) (1 trial)

octreotate (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Neuroendocrine (Phase 2)

Neuroendocrine Tumors (Phase 3)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 5